2196 — Shanghai Fosun Pharmaceutical Co Income Statement
0.000.00%
Last trade - 00:00
- HK$32.76bn
- HK$67.46bn
- CNY41.40bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | CAS | CAS | CAS | CAS | CAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 28,585 | 30,307 | 39,005 | 43,952 | 41,400 |
Cost of Revenue | |||||
Gross Profit | 17,029 | 16,811 | 18,712 | 20,696 | 19,683 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 24,102 | 25,596 | 32,710 | 39,309 | 38,097 |
Operating Profit | 4,484 | 4,711 | 6,295 | 4,642 | 3,302 |
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4,526 | 4,678 | 6,054 | 4,574 | 3,265 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3,744 | 3,940 | 4,987 | 3,947 | 2,895 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 3,322 | 3,663 | 4,735 | 3,731 | 2,386 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3,322 | 3,663 | 4,735 | 3,731 | 2,386 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.855 | 1.38 | 1.24 | 1.34 | 0.69 |
Dividends per Share |